Access, cost, and policy

Many people with Crohn’s look to short social videos for information. Moderate-quality and misleading reels could influence treatment decisions, emotional wellbeing, and when people seek medical care.

Based on the title and source metadata, this appears to be a clinical study related to Crohn's disease, Inflammatory bowel disease, and Research and clinical trials. The original article is from msn.com.

There are many new drugs and trials underway for Crohn’s disease, which could expand future treatment options. Recent phase 2 and phase 3 starts from major pharma show active investment in IBD research.

A new national approval means guselkumab (TREMFYA) may soon be an available treatment option for people with Crohn’s disease or ulcerative colitis in Egypt, potentially expanding choices for moderate-to-severe disease....

This could expand an approved, gut-targeted biologic (vedolizumab/ENTYVIO) to children as young as 2 with UC or Crohn’s disease, addressing a pediatric treatment gap if the FDA approves the sBLA. Families and clinicians...

Cure8 indexed this Crohn's and IBD-related source from syneoshealth.com. It is tagged for Ulcerative colitis, Crohn's disease, and Community and awareness. Open the original article for the full details.

Racial and socioeconomic factors can delay Crohn’s diagnosis and limit access to specialist care, testing, and medications — which can lead to worse outcomes. Knowing these disparities can help patients, caregivers, and...

Based on the title and source metadata, this appears to be a patient story related to Crohn's disease, Inflammatory bowel disease, and Access, cost, and policy. The original article is from msn.com.

Based on the title and source metadata, this appears to be a patient education related to Crohn's disease, Inflammatory bowel disease, and Access, cost, and policy. The original article is from msn.com.

Cure8 found this source from tipranks.com, but the page could not be read reliably yet. It is tagged for Crohn's disease, Inflammatory bowel disease, and Ustekinumab. Open the original article for the full details.

New clinical results for TREMFYA in perianal fistulizing Crohn's disease and positive data for another J&J IBD drug could signal future treatment options or regulatory milestones that matter to people with Crohn's and...

IBD affects many parts of life, not just the digestive tract — symptoms, mental health, work and school can all be disrupted. The article highlights support options and a free webinar/guide from a patient advocacy group...

New long-term and real-world data on SKYRIZI and RINVOQ were presented at DDW, which may influence how clinicians, payers, and patients view these options for Crohn's disease and ulcerative colitis.

Market reports signal where research and new drug investment are going, which can affect future treatment options, drug availability, and pricing. For people living with Crohn’s disease, trends toward more biologics,...

A subcutaneous induction option for SKYRIZI could let people with Crohn’s start and continue treatment with injections instead of beginning with an IV infusion, which may affect convenience, time in clinic, and infusion...

Financial support programs can reduce education-related stress for students managing Crohn’s or colitis and recognize the challenges of juggling symptoms and school. If you or a family member with IBD are pursuing...

Cure8 could only read part of this source from ntnews.com.au, so this card uses cautious topic tags instead of a full summary. It is tagged for Inflammatory bowel disease, Crohn's disease, and Access, cost, and policy.

Based on the title and source metadata, this appears to be a regulatory update related to Ustekinumab, IL-12/23 inhibitor, and Medications. The original article is from msn.com.

Rising IBD cases, limited specialist access, and cultural differences in decision-making may delay diagnosis, worsen outcomes, and increase misinformation.

An interchangeable biosimilar to ustekinumab could expand access and lower costs for people with Crohn’s disease and ulcerative colitis who use Stelara. Pharmacists may be able to substitute the biosimilar for the...

Based on the title and source metadata, this appears to be a market or business news related to Ulcerative colitis, Crohn's disease, and Guselkumab. The original article is from firstwordpharma.com.

Veterans with Crohn’s disease may be eligible for VA disability benefits via direct or secondary service-connection paths. The article explains what evidence the VA typically requires and how conditions like PTSD or...

An FDA interchangeability approval for a biosimilar to ustekinumab could make a lower-cost alternative more available for people with Crohn’s disease or ulcerative colitis who use Stelara. It’s primarily a regulatory and...

Formulary listings for Yesintek (ustekinumab biosimilar) could make an established IBD treatment more affordable and accessible for people with Crohn’s disease or ulcerative colitis. Wider payer coverage may affect which...

Based on the title and source metadata, this appears to be a market or business news related to Access, cost, and policy. The original article is from msn.com.

Cure8 found this source from ksn.com, but the page could not be read reliably yet. It is tagged for Access, cost, and policy. Open the original article for the full details.

Awareness campaigns can help people recognise IBD symptoms earlier and reduce stigma, which may shorten diagnostic delays and encourage people to seek care. This is especially relevant given rising IBD incidence reported...

Based on the title and source metadata, this appears to be a patient story related to Crohn's disease, Inflammatory bowel disease, and Community and awareness. The original article is from msn.com.

Cure8 found this source from businessmirror.com.ph, but the page could not be read reliably yet. It is tagged for Crohn's disease, Inflammatory bowel disease, and Access, cost, and policy. Open the original article for...

Market reports can signal which drugs, companies, and biosimilars are becoming more available and may affect access and cost. Announcements about biosimilars could influence treatment affordability and prescribing...

This video quickly outlines the range of medical treatments now available for Crohn’s disease, including newer approvals. Knowing drug classes and recent options can help patients and clinicians discuss treatment plans...

High medication costs and insurance rules can change what treatments a person with Crohn’s can actually get. Knowing about copay assistance and patient-access programs can lower or eliminate out-of-pocket cost and help...

Many people with Crohn's disease rely on expensive biologic infusions; arrangements to get free or subsidized drug supplies through employer-contracted middlemen can suddenly fail and leave patients with large unexpected...

Market reports can indicate which drugs, companies, and research programs are getting investment and attention—information that may affect availability, new treatment development, and drug pricing. News about industry...

First-person stories show real-world problems people with Crohn’s face: treatment costs, surgery and ostomy life, relapses and complications, and mental-health impacts. The article highlights a new patient-run nonprofit...

Based on the title and source metadata, this appears to be a regulatory update related to Crohn's disease, Inflammatory bowel disease, and Guselkumab. The original article is from firstwordpharma.com.

This article reports a local government website changing hosts and domain names, which could affect how residents access county services online.

The study highlights racial and ethnic disparities in access to IBD care — including specialist visits, use of advanced therapies, and emergency services — which can affect disease management and outcomes. Recognizing...

Cure8 indexed this Crohn's and IBD-related source from openpr.com. It is tagged for Crohn's disease, Inflammatory bowel disease, and Access, cost, and policy. Open the original article for the full details.

Based on the title and source metadata, this appears to be a patient education related to Access, cost, and policy. The original article is from msn.com.

Patent expirations can allow biosimilars or generics to enter the U.S. market, which may lower costs and change which versions of IBD biologic drugs are available. Patients on affected medicines should be aware because...

Cure8 could only read part of this source from law360.com, so this card uses cautious topic tags instead of a full summary. It is tagged for Crohn's disease and Access, cost, and policy.

Regulatory approval means ustekinumab (Stelara) can now be prescribed in the EU for some children with moderate‑to‑severe Crohn’s disease who haven’t responded to other treatments. This expands treatment options for...

A new EC approval makes ustekinumab an approved treatment option for children and adolescents (≥40 kg) with moderate–severe Crohn’s disease, potentially expanding choices for patients who haven’t responded to other...

Based on the title and source metadata, this appears to be an observational study related to Inflammatory bowel disease and Access, cost, and policy. The original article is from msn.com.

A CHMP recommendation is a major regulatory step toward EU approval — that could mean a new biologic option (guselkumab/Tremfya) for adults with moderate–severe Crohn’s disease, including people who haven’t responded to...

This roundup highlights many drugs and trials in development for Crohn’s disease, including late‑stage studies of biologics and newer oral agents — information that could affect future treatment options. Patients on...

This report outlines which drugs and companies are shaping Crohn’s disease treatment options and predicts market shifts that may affect treatment availability, costs, and future therapy choices.